CN101415437A - 用于家禽疫苗接种的干粉组合物和系统 - Google Patents
用于家禽疫苗接种的干粉组合物和系统 Download PDFInfo
- Publication number
- CN101415437A CN101415437A CNA2007800089704A CN200780008970A CN101415437A CN 101415437 A CN101415437 A CN 101415437A CN A2007800089704 A CNA2007800089704 A CN A2007800089704A CN 200780008970 A CN200780008970 A CN 200780008970A CN 101415437 A CN101415437 A CN 101415437A
- Authority
- CN
- China
- Prior art keywords
- virus
- vaccination
- poultry
- dry powder
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 129
- 238000002255 vaccination Methods 0.000 title claims abstract description 118
- 244000144977 poultry Species 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 229960005486 vaccine Drugs 0.000 claims abstract description 99
- 239000002245 particle Substances 0.000 claims abstract description 62
- 239000000969 carrier Substances 0.000 claims abstract description 11
- 241000700605 Viruses Species 0.000 claims description 67
- 239000002131 composite material Substances 0.000 claims description 54
- 241000271566 Aves Species 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000001694 spray drying Methods 0.000 claims description 19
- 229920000642 polymer Polymers 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 9
- 241000403254 Turkey hepatitis virus Species 0.000 claims description 8
- -1 poly(ethylene oxide) Polymers 0.000 claims description 8
- 206010014599 encephalitis Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 claims description 6
- 241000711450 Infectious bronchitis virus Species 0.000 claims description 6
- 241001246431 Goose hemorrhagic polyomavirus Species 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 150000005846 sugar alcohols Polymers 0.000 claims description 5
- 241000701242 Adenoviridae Species 0.000 claims description 4
- 241000712892 Arenaviridae Species 0.000 claims description 4
- 241001292006 Arteriviridae Species 0.000 claims description 4
- 241001533362 Astroviridae Species 0.000 claims description 4
- 241000714198 Caliciviridae Species 0.000 claims description 4
- 241001533399 Circoviridae Species 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
- 241000711950 Filoviridae Species 0.000 claims description 4
- 241000710781 Flaviviridae Species 0.000 claims description 4
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 claims description 4
- 229920001503 Glucan Polymers 0.000 claims description 4
- 241001517118 Goose parvovirus Species 0.000 claims description 4
- 241000700739 Hepadnaviridae Species 0.000 claims description 4
- 241000712464 Orthomyxoviridae Species 0.000 claims description 4
- 241000711504 Paramyxoviridae Species 0.000 claims description 4
- 241000701945 Parvoviridae Species 0.000 claims description 4
- 241000150350 Peribunyaviridae Species 0.000 claims description 4
- 241000709664 Picornaviridae Species 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 206010035742 Pneumonitis Diseases 0.000 claims description 4
- 241000700625 Poxviridae Species 0.000 claims description 4
- 241000702247 Reoviridae Species 0.000 claims description 4
- 241000712907 Retroviridae Species 0.000 claims description 4
- 241000711931 Rhabdoviridae Species 0.000 claims description 4
- 241000702670 Rotavirus Species 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 241000710924 Togaviridae Species 0.000 claims description 4
- 241000711517 Torovirus Species 0.000 claims description 4
- 241000711508 Turkey coronavirus Species 0.000 claims description 4
- 108700010877 adenoviridae proteins Proteins 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920001661 Chitosan Chemical class 0.000 claims description 2
- 241000206575 Chondrus crispus Species 0.000 claims description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 229920003232 aliphatic polyester Polymers 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000001913 cellulose Chemical class 0.000 claims description 2
- 229920002678 cellulose Chemical class 0.000 claims description 2
- 238000007385 chemical modification Methods 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims 3
- 244000045947 parasite Species 0.000 claims 3
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims 2
- 229920001100 Polydextrose Polymers 0.000 claims 1
- 239000001259 polydextrose Substances 0.000 claims 1
- 235000013856 polydextrose Nutrition 0.000 claims 1
- 229940035035 polydextrose Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 229920000249 biocompatible polymer Polymers 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000011081 inoculation Methods 0.000 description 21
- 241000287828 Gallus gallus Species 0.000 description 15
- 238000009826 distribution Methods 0.000 description 14
- 239000003570 air Substances 0.000 description 13
- 239000000443 aerosol Substances 0.000 description 11
- 239000008187 granular material Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 241000711404 Avian avulavirus 1 Species 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 244000005700 microbiome Species 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000005507 spraying Methods 0.000 description 7
- 238000000889 atomisation Methods 0.000 description 6
- 206010064097 avian influenza Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000009849 deactivation Effects 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 241000204022 Mycoplasma gallisepticum Species 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 231100000053 low toxicity Toxicity 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 241000606161 Chlamydia Species 0.000 description 3
- 206010013496 Disturbance in attention Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 238000011238 DNA vaccination Methods 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 238000003109 Karl Fischer titration Methods 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 208000027954 Poultry disease Diseases 0.000 description 2
- 206010037151 Psittacosis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 201000000901 ornithosis Diseases 0.000 description 2
- 238000011020 pilot scale process Methods 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 241000701802 Aviadenovirus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000588851 Bordetella avium Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 240000007762 Ficus drupacea Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000702626 Infectious bursal disease virus Species 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001135620 Ornithobacterium rhinotracheale Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010035673 Pneumonia chlamydial Diseases 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 208000006316 Respirovirus Infections Diseases 0.000 description 1
- 241000712909 Reticuloendotheliosis virus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000012768 mass vaccination Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000005645 nematicide Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000025926 respirovirus infectious disease Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 229940074409 trehalose dihydrate Drugs 0.000 description 1
- 150000003625 trehaloses Chemical class 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 238000004017 vitrification Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (25)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06005245.3 | 2006-03-15 | ||
EP06005245A EP1834651A1 (en) | 2006-03-15 | 2006-03-15 | Compositions and methods for veterinary vaccination |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101415437A true CN101415437A (zh) | 2009-04-22 |
Family
ID=37564170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007800089704A Pending CN101415437A (zh) | 2006-03-15 | 2007-03-15 | 用于家禽疫苗接种的干粉组合物和系统 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20090041852A1 (zh) |
EP (2) | EP1834651A1 (zh) |
JP (1) | JP2009529558A (zh) |
CN (1) | CN101415437A (zh) |
BR (1) | BRPI0708983A2 (zh) |
DK (1) | DK1993605T3 (zh) |
ES (1) | ES2389864T3 (zh) |
MX (1) | MX2008011701A (zh) |
PL (1) | PL1993605T3 (zh) |
PT (1) | PT1993605E (zh) |
RU (1) | RU2450828C2 (zh) |
SI (1) | SI1993605T1 (zh) |
UA (1) | UA96754C2 (zh) |
WO (1) | WO2007104562A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083659A (zh) * | 2013-01-18 | 2013-05-08 | 北京华夏兴洋生物科技有限公司 | 新型无油佐剂制备方法及用途 |
CN109260467A (zh) * | 2018-08-17 | 2019-01-25 | 山东信得科技股份有限公司 | 一种预防雏鹅痛风症状的疫苗 |
CN113599513A (zh) * | 2020-10-23 | 2021-11-05 | 青岛大学 | 一种适用于咽喉部接种的新型冠状病毒疫苗的制备方法及接种方法 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1834651A1 (en) * | 2006-03-15 | 2007-09-19 | Universiteit Gent | Compositions and methods for veterinary vaccination |
US7998502B2 (en) * | 2008-03-24 | 2011-08-16 | Advanced Bionutrition Corp. | Encapsulated vaccines for the oral vaccination and boostering of fish and other animals |
US8778384B2 (en) | 2008-03-24 | 2014-07-15 | Advanced Bionutrition Corporation | Compositions and methods for encapsulating vaccines for the oral vaccination and boostering of fish and other animals |
WO2010037027A2 (en) * | 2008-09-26 | 2010-04-01 | Auburn University | Immunization of avians by mucosal administration of non-replicating vectored vaccines |
WO2010135495A2 (en) | 2009-05-20 | 2010-11-25 | Aeras Global Tb Vaccine Foundation | Stable, spray dried, immunogenic, viral compositions |
JP5550277B2 (ja) * | 2009-07-23 | 2014-07-16 | 長谷川香料株式会社 | 保存安定性に優れた粉末組成物 |
US8486418B2 (en) * | 2009-08-21 | 2013-07-16 | Merial Limited | Recombinant avian paramyxovirus vaccine and method for making and using thereof |
US20130071421A1 (en) * | 2009-10-02 | 2013-03-21 | W. Ian Lipkin | Turkey viral hepatitis virus and uses thereof |
CN102772799A (zh) * | 2012-05-31 | 2012-11-14 | 郑州后羿制药有限公司 | 一种鸭病毒性肝炎、鸭瘟二联卵黄抗体冻干粉及其制备方法 |
JP7051132B2 (ja) * | 2016-09-16 | 2022-04-11 | ロイコケア・アクチェンゲゼルシャフト | ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法 |
WO2018050873A1 (en) | 2016-09-16 | 2018-03-22 | Leukocare Ag | A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
CN107019707A (zh) * | 2017-03-14 | 2017-08-08 | 杨凌绿方生物工程有限公司 | 一种鸡胚成纤维细胞产品冻干工艺方法 |
TR201718859A2 (tr) * | 2017-11-27 | 2017-12-21 | Bilge Kaan Tekelioglu | Siğirlarin gangrenli̇ nezlesi̇ i̇çi̇n aşi ve aşinin üreti̇m yöntemi̇ |
EP3698773A1 (en) | 2019-02-21 | 2020-08-26 | Università degli Studi di Parma | Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58105310U (ja) * | 1982-01-11 | 1983-07-18 | 貝原 睦衛 | ひよこ用ワクチン点眼装置 |
JPS5924019U (ja) * | 1982-08-05 | 1984-02-15 | イカリ消毒株式会社 | 動物用ワクチン投与装置 |
RU2035909C1 (ru) * | 1993-06-02 | 1995-05-27 | Виноходов Владимир Олегович | Препарат для профилактики и лечения заболеваний птиц |
GB9607035D0 (en) * | 1996-04-03 | 1996-06-05 | Andaris Ltd | Spray-dried microparticles as therapeutic vehicles |
SE9801288D0 (sv) * | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
US6651655B1 (en) * | 2000-01-18 | 2003-11-25 | Quadrant Technologies Limited | Inhaled vaccines |
KR20050011741A (ko) * | 2002-04-11 | 2005-01-29 | 메드이뮨 백신즈 인코포레이티드 | 분무 건조에 의한 생물학적 활성 물질의 보존 |
WO2005123131A2 (en) * | 2004-06-14 | 2005-12-29 | Medimmune Vaccines, Inc. | High pressure spray-dry of bioactive materials |
AU2002951692A0 (en) * | 2002-09-23 | 2002-10-17 | Vital Biotech (Hong Kong) Limited | Improvements in or relating to vaccines |
EP1581639A4 (en) * | 2002-12-17 | 2006-03-08 | Medimmune Vaccines Inc | HIGH PRESSURE PULVISATION OF BIOACTIVE MATERIALS |
US20050207983A1 (en) * | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
EP1834651A1 (en) * | 2006-03-15 | 2007-09-19 | Universiteit Gent | Compositions and methods for veterinary vaccination |
-
2006
- 2006-03-15 EP EP06005245A patent/EP1834651A1/en not_active Withdrawn
-
2007
- 2007-03-15 EP EP07711957A patent/EP1993605B1/en not_active Not-in-force
- 2007-03-15 DK DK07711957.6T patent/DK1993605T3/da active
- 2007-03-15 UA UAA200812168A patent/UA96754C2/ru unknown
- 2007-03-15 SI SI200731007T patent/SI1993605T1/sl unknown
- 2007-03-15 US US12/293,019 patent/US20090041852A1/en not_active Abandoned
- 2007-03-15 RU RU2008140745/15A patent/RU2450828C2/ru not_active IP Right Cessation
- 2007-03-15 ES ES07711957T patent/ES2389864T3/es active Active
- 2007-03-15 MX MX2008011701A patent/MX2008011701A/es active IP Right Grant
- 2007-03-15 PL PL07711957T patent/PL1993605T3/pl unknown
- 2007-03-15 JP JP2008558721A patent/JP2009529558A/ja active Pending
- 2007-03-15 CN CNA2007800089704A patent/CN101415437A/zh active Pending
- 2007-03-15 BR BRPI0708983-0A patent/BRPI0708983A2/pt not_active Application Discontinuation
- 2007-03-15 PT PT07711957T patent/PT1993605E/pt unknown
- 2007-03-15 WO PCT/EP2007/002284 patent/WO2007104562A1/en active Application Filing
-
2010
- 2010-12-16 US US12/970,225 patent/US20110150940A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083659A (zh) * | 2013-01-18 | 2013-05-08 | 北京华夏兴洋生物科技有限公司 | 新型无油佐剂制备方法及用途 |
CN109260467A (zh) * | 2018-08-17 | 2019-01-25 | 山东信得科技股份有限公司 | 一种预防雏鹅痛风症状的疫苗 |
CN109260467B (zh) * | 2018-08-17 | 2021-08-20 | 山东信得科技股份有限公司 | 一种预防雏鹅痛风症状的疫苗 |
CN113599513A (zh) * | 2020-10-23 | 2021-11-05 | 青岛大学 | 一种适用于咽喉部接种的新型冠状病毒疫苗的制备方法及接种方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1993605B1 (en) | 2012-06-27 |
US20110150940A1 (en) | 2011-06-23 |
JP2009529558A (ja) | 2009-08-20 |
BRPI0708983A2 (pt) | 2011-06-21 |
RU2450828C2 (ru) | 2012-05-20 |
PL1993605T3 (pl) | 2012-12-31 |
MX2008011701A (es) | 2008-11-27 |
EP1993605A1 (en) | 2008-11-26 |
PT1993605E (pt) | 2012-09-17 |
US20090041852A1 (en) | 2009-02-12 |
DK1993605T3 (da) | 2012-09-10 |
UA96754C2 (ru) | 2011-12-12 |
SI1993605T1 (sl) | 2012-11-30 |
ES2389864T3 (es) | 2012-11-02 |
EP1834651A1 (en) | 2007-09-19 |
RU2008140745A (ru) | 2010-04-20 |
WO2007104562A1 (en) | 2007-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101415437A (zh) | 用于家禽疫苗接种的干粉组合物和系统 | |
Audouy et al. | Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization | |
JP6779950B2 (ja) | 室温安定であるワクチンの乾燥製剤 | |
RU2339400C2 (ru) | Стабилизированная вакцинная композиция для стимулирования иммунного ответа и способ ее получения | |
Smith et al. | Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus | |
RU2559527C2 (ru) | Рекомбинантная вакцина от птичьего гриппа и её применение | |
CN101312742A (zh) | 用于冷冻干燥的疫苗的稳定剂 | |
JP4646516B2 (ja) | 吸着したポリペプチド含有分子を有する微粒子 | |
JP2000507825A (ja) | 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス | |
Tomar et al. | Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge | |
US20140154288A1 (en) | Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response | |
CN103841963B (zh) | 用于生物产品特别是疫苗的真空辅助保存 | |
Fawzy et al. | Nanoparticles as a novel and promising antiviral platform in veterinary medicine | |
CN109045291B (zh) | 一种猪支原体肺炎气溶胶活疫苗及其制备方法 | |
Corbanie et al. | Vaccination of broiler chickens with dispersed dry powder vaccines as an alternative for liquid spray and aerosol vaccination | |
KR20120131725A (ko) | 고병원성 조류인플루엔자 a h5n1 바이러스 유사입자 및 이를 이용한 가금용 백신 | |
CN100435844C (zh) | 大肠杆菌热不稳定毒素作为鸟类和家禽的佐剂的用途 | |
TWI267553B (en) | An avian embryo particulate biomass for the production of antigens | |
Alsakini et al. | Adjuvant effects of novel water/oil emulsion formulations on immune responses against infectious bronchitis (IB) vaccine in mice | |
Huyge | Dry powder vaccines for mass vaccination of poultry: new formulations, comparison with liquid vaccines and feasibility to decrease adverse vaccinal reactions | |
AU2003264166A1 (en) | Improvements in or relating to vaccines | |
CN116966292A (zh) | 一种兽用疫苗佐剂、制备方法及其应用 | |
US20140205993A1 (en) | Recombinant avian influenza vaccine and uses thereof | |
Shawky et al. | Comparative Protective Efficiency of Different Stabilizers for Live Newcastle Disease Virus Vaccine Production | |
Park et al. | Release of Newcastle disease virus vaccine from chitosan microspheres in vitro and in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: J.P.Lemmon Inventor after: Vervaet Chris Inventor after: Corbanie Evy Inventor after: J, H, H von AIKE Inventor after: W, J, M, Rand Inventor before: J.P.Lemmon Inventor before: Vervaet Chris Inventor before: Corbanie Evy |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: REMON JEAN PAUL C. VERVAET CORBANIE EVY TO: REMON JEAN PAUL C. VERVAET CORBANIE EVY J. H. H. VON IKE W. J. M. LANDMAN |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20090422 |